{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:38:38Z","timestamp":1773279518044,"version":"3.50.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Pediatr Emer Care"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>This study aimed to determine if the use of intranasal (IN) fentanyl in the pediatric emergency department of 2 to 5 \u03bcg\/kg at doses greater than 100 \u03bcg is associated with adverse events in pediatric patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed a retrospective chart review of patients receiving IN fentanyl at an urban, tertiary care emergency department in Memphis, TN, from January 1, 2011, to December 31, 2017. All adverse events documented through the hospital's voluntary safety reporting system involving IN fentanyl were reviewed to determine patient outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 3205 patients received greater than 100 \u03bcg of IN fentanyl during the study period from 2011 to 2017. The average (SD) patient age was 13.7 (2.65) years, ranging from 5 to 18 years. The mean (SD) initial dose was 162 (30) \u03bcg ranging from 102 to 265 \u03bcg (2 doses were given greater than 200 \u03bcg in the study period). Initial average (SD) dose for weight was 2.62 (0.5) \u03bcg\/kg. A total of 13 adverse events were documented, with only 3 occurring at doses greater than 100 \u03bcg. No patients required the reversal agent naloxone or invasive respiratory support.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>To our knowledge, this is the first study using doses greater than 100 \u03bcg of IN fentanyl in a pediatric population. Our results indicate that fentanyl can be safely administered at doses of greater than 100 \u03bcg without any clinically significant adverse outcomes observed for 7 years of use. It is our hope that this information will increase utilization of IN fentanyl for treatment of acute pain in emergency departments and in the prehospital setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pec.0000000000002627","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T15:05:53Z","timestamp":1643641553000},"page":"e447-e450","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["The Safety of High-Dose Intranasal Fentanyl in the Pediatric Emergency Department"],"prefix":"10.1097","volume":"38","author":[{"given":"Tucker","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camden","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Snider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudy","family":"Kink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250504","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/PEC.0b013e31822877f7","article-title":"Pain assessment for children: overcoming challenges and optimizing care","volume":"27","year":"2011","journal-title":"Pediatr Emerg Care"},{"key":"bib2-20250504","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2310\/8000.2013.131261","article-title":"Reported practice variation in pediatric pain management: a survey of Canadian pediatric emergency physicians","volume":"16","year":"2014","journal-title":"CJEM"},{"key":"bib3-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jemermed.2017.01.020","article-title":"Review of intranasally administered medications for use in the emergency department","volume":"53","year":"2017","journal-title":"Am J Emerg Med"},{"key":"bib4-20250504","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1345\/aph.1L168","article-title":"Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery","volume":"42","year":"2008","journal-title":"Ann Pharmacother"},{"key":"bib5-20250504","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jppr200333159","article-title":"Pharmacokinetics of nasal fentanyl","volume":"33","year":"2003","journal-title":"J Pharm Pract Res"},{"key":"bib6-20250504","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.annemergmed.2006.06.016","article-title":"A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department","volume":"49","year":"2007","journal-title":"Ann Emerg Med"},{"key":"bib7-20250504","first-page":"CD009942","article-title":"Intranasal fentanyl for the management of acute pain in children","volume":"2014","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"bib8-20250504","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1542\/peds.2008-1444","article-title":"Research to practice in pediatric pain: what are we missing?","volume":"122","year":"2008","journal-title":"Pediatrics"},{"key":"bib9-20250504","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1542\/peds.2010-0616","article-title":"Intranasal medication delivery for children: a brief review and update","volume":"126","year":"2010","journal-title":"Pediatrics"},{"key":"bib10-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1442-2026.2002.00344.x","article-title":"Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study","volume":"14","year":"2002","journal-title":"Emerg Med (Fremantle)"},{"key":"bib11-20250504","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annemergmed.2014.09.024","article-title":"The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries","volume":"65","year":"2015","journal-title":"Ann Emerg Med"},{"key":"bib12-20250504","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.annemergmed.2017.02.015","article-title":"When to pick the nose: out-of-hospital and emergency department intranasal administration of medications","volume":"70","year":"2017","journal-title":"Ann Emerg Med"},{"key":"bib14-20250504","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1034\/j.1399-6576.2002.460702.x","article-title":"Nasal administration of opioids for pain management in adults","volume":"46","year":"2002","journal-title":"Anaesthesiol Scand"},{"key":"bib15-20250504","first-page":"288","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","year":"2009","journal-title":"J Pharm Sci"},{"key":"bib16-20250504","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.clinthera.2009.12.015","article-title":"A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally","volume":"31","year":"2009","journal-title":"Clin Ther"},{"key":"bib17-20250504","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.annemergmed.2016.08.450","article-title":"Optimal volume of administration of intranasal midazolam in children: a randomized clinical trial","volume":"69","year":"2017","journal-title":"Ann Emerg Med"},{"key":"bib18-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1742-6723.2011.01391.x","article-title":"Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial","volume":"23","year":"2011","journal-title":"Emerg Med Australas"},{"key":"bib19-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajem.2018.05.036","article-title":"Safety and effectiveness of intranasal midazolam and fentanyl used in combination in the pediatric emergency department","volume":"37","year":"2019","journal-title":"Am J Emerg Med"},{"key":"bib20-20250504","first-page":"2019","article-title":"Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures","volume":"143","year":"2019","journal-title":"Pediatrics"}],"container-title":["Pediatric Emergency Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PEC.0000000000002627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T19:01:00Z","timestamp":1746385260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PEC.0000000000002627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pec.0000000000002627","relation":{},"ISSN":["1535-1815","0749-5161"],"issn-type":[{"value":"1535-1815","type":"electronic"},{"value":"0749-5161","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}